Rewalk robotics ltd. LFWD.US Overview
LFWD AI Analysis & Strategy
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
LFWD Current Performance
-0.40%
Rewalk robotics ltd.
0.98%
Avg of Sector
0.83%
S&P500
LFWD Key Information
LFWD Financial Forecast
Unit : USD
LFWD Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.46 | 37% | 39.4% | 5.03M | -4.7% | -23.9% | -202.5% |
| 2024Q3 | -0.38 | -8.6% | 90% | 7.55M | 9.6% | 0.2% | -50.3% |
| 2024Q1 | -0.5 | 8.4% | -5.7% | 6.71M | 401.6% | -8.1% | -118.8% |
| 2023Q4 | -0.73 | -43.6% | 4.3% | 5.28M | 329.5% | -4.8% | -81.9% |
| 2023Q3 | -0.35 | 42% | -61.5% | 6.88M | 215.9% | -4.7% | -171% |
LFWD Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.